Measurement of Experimental Polar Surface Area Using Supercritical Fluid Chromatography

Significance of the topic

Supercritical fluid chromatography (SFC)-based Experimental Polar Surface Area (EPSA) provides an empirical measure of the exposed polar surface of molecules that complements calculated topological PSA (TPSA). EPSA better captures conformational effects and intramolecular hydrogen bonding that influence membrane permeability, and therefore improves permeability assessment for cyclic peptides and medium-sized druglike molecules where TPSA often overestimates polarity.

Objectives and overview of the study

• Demonstrate measurement of EPSA using SFC retention times on a Nexera UC system combined with UV photodiode array (PDA) and a single‑quadrupole mass spectrometer (LCMS-2050).
• Develop a calibration curve relating SFC retention time to TPSA for a set of standard small molecules and use it to derive EPSA values for peptide-like drugs (cyclosporine A and ritonavir).
• Show a practical, high-throughput workflow and open access operation using Open Solution software, including system suitability testing (SST) and automated instrument conditioning to ensure reliable EPSA results in shared laboratory environments.

Methodology

• Calibration: Nine small-molecule standards (including lidocaine, antipyrine, chlorpromazine, pindolol, desipramine, diclofenac, m‑nitrobenzoic acid, bumetanide, furosemide) were prepared at 1.0 g/L in DMSO. Known TPSA values were used to build a calibration relating SFC retention time to exposed polar surface area (EPSA).
• SFC conditions (representative): CO2 mobile phase with methanolic modifier (20 mM ammonium formate in methanol). Gradient from 5% to 98% organic over ~5.5 min; flow rate 4.0 mL/min; back‑pressure regulator ~20.4 MPa; column temperature around 40–70 °C depending on run specifics; injection volume 2 μL for standards (1.0 g/L).
• Detection: PDA (UV 254 nm) plus LCMS-2050 single‑quadrupole mass spectrometer using ESI/APCI (DUIS) in positive and negative modes (scan m/z 100–2000). MS parameters included typical nebulizing and drying gas flows, DL/desolvation temperatures and interface voltages ±3.0 kV/-2.0 kV.
• Calibration curve generation: Retention times from PDA and MS chromatograms were correlated with TPSA; both detectors produced highly linear calibration (R² ≈ 0.997).
• EPSA determination: Retention times of target peptides were converted to EPSA using the calibration. System suitability tests (SST) based on retention time (example: diclofenac target retention 2.100–2.200 min) were used to verify instrument readiness prior to EPSA calculations.

Used instrumentation

• SFC system: Nexera UC (Shimadzu) with CO2 pump, organic solvent pump, autosampler, column oven and back-pressure regulator.
• Column: Phenomenex Chirex chiral columns listed in the application note (50 mm × 4.6 mm I.D., 5 μm particle size) for the described runs.
• Detectors: Photodiode array (PDA) detector (UV 254 nm) and LCMS-2050 single‑quadrupole MS (ESI/APCI DUIS).
• Software and automation: Open Solution open‑access software for scheduling, automatic conditioning, SST execution, results handling and open-access sample submission.

Main results and discussion

• Calibration performance: The retention-time vs TPSA calibration covered an EPSA range of ~47–230 Ų and showed excellent linearity. Example linear fits from the report: y ≈ 54.0 x + 25 with R² ≈ 0.997 (PDA and MS-based fits similar), enabling reliable conversion of retention times to EPSA.
• Measured peptide EPSA vs TPSA: Cyclosporine A and ritonavir produced substantially lower EPSA values than computed TPSA—Cyclosporine A: TPSA 278 Ų vs EPSA 62 Ų; Ritonavir: TPSA 145 Ų vs EPSA 75 Ų. These differences reflect shielding of polar groups by conformation and intramolecular hydrogen bonds, phenomena not captured in TPSA.
• Detector complementarity: Combination of PDA and MS broadens the detectable compound set—PDA is selective for UV‑active compounds, while MS detects ionizable species including UV‑silent analytes (e.g., cyclosporine A poorly detected by PDA but visible by MS). EPSA can therefore be calculated from retention times found in either detector.
• Quality assurance: Regular SSTs (example shown for diclofenac) detect deviations such as changes in modifier salt concentration that shift retention times and would corrupt EPSA calculations. Open Solution automates SST execution, evaluation and trend visualization (SST Viewer), facilitating immediate identification of failing conditions.

Benefits and practical applications

• Improved permeability assessment: EPSA gives experimentally grounded estimates of exposed polar surface for cyclic peptides and medium‑sized molecules, aiding prioritization in medicinal chemistry when TPSA is unreliable.
• High throughput and reproducibility: Short SFC runs and small injection volumes allow rapid analysis of many compounds. Open Solution enforces standardized methods, automated conditioning and SST checks to reduce user-dependent variability in shared laboratories.
• Broader analyte coverage: Using PDA + MS increases the fraction of compounds for which retention times (and thus EPSA) can be obtained, including non‑UV chromophores and difficult matrices encountered in early drug discovery samples.
• Operational efficiency: Features such as scheduled auto‑startup, auto‑idle (low flow), and auto‑shutdown conserve solvent and instrument life while keeping systems ready for users in an open access setting.

Future trends and potential applications

• Integration with high-throughput synthesis: Embedding EPSA measurement into automated screening pipelines will accelerate selection of permeable candidates, especially for stapled peptides, cyclic peptides and other medium‑sized modalities.
• Refinement of calibration libraries: Expanding the range and diversity of calibration standards (including larger and more conformationally complex molecules) will improve EPSA accuracy across chemical space.
• Advanced data fusion: Combining EPSA with in vitro permeability assays and computational conformer sampling could yield improved predictive models for ADME properties of challenging scaffolds.
• Wider detector coupling: Incorporating higher‑sensitivity MS or orthogonal detectors could increase detection rates for poorly ionizable or low‑abundance species, enabling EPSA determination for more compound classes.

Conclusion

SFC-derived EPSA, calibrated against standards with known TPSA, offers a robust experimental metric for exposed polar surface area that better reflects molecular conformation than TPSA alone. The combination of PDA and single‑quadrupole MS detection increases analyte coverage for EPSA extraction. Implementing Open Solution for open access operation, automated conditioning and SST monitoring secures data quality and throughput in multiuser drug discovery environments. Together, these elements make EPSA a practical tool to guide permeability assessment and candidate selection for cyclic peptides and medium‑sized drug candidates.

Reference

1. Palm K., Stenberg P., Luthman K., et al. Polar Molecular Surface Properties Predict the Intestinal Absorption of Drugs in Humans. Pharm. Res. 1997;14:568–571.
2. Wang Y.-T., Price E., et al. High‑Throughput SFC‑MS/MS Method to Measure EPSA and Predict Human Permeability. J. Med. Chem. 2024;67(16):13765–13777.
3. Veber D.F., Johnson S.R., et al. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. J. Med. Chem. 2002;45(12):2615–2623.
4. Pajouhesh H., Lenz G.R. Medicinal chemical properties of successful central nervous system drugs. Neurotherapeutics 2005;2:541–553.
5. Goetz G.H., Philippe L., Shapiro M.J. EPSA: A Novel Supercritical Fluid Chromatography Technique Enabling the Design of Permeable Cyclic Peptides. ACS Med. Chem. Lett. 2014;5(10):1167–1172.